Anabolic treatment with GH, IGF-I, or anabolic steroids in patients with HIV-associated wasting.

[1]  M. Schambelan,et al.  Effects of recombinant human growth hormone on fat distribution in patients with human immunodeficiency virus-associated wasting. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  A. Klibanski,et al.  Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  D. Schoenfeld,et al.  Effects of Testosterone and Progressive Resistance Training in Eugonadal Men with AIDS Wasting , 2000, Annals of Internal Medicine.

[4]  M. Elia,et al.  Phase angle from bioelectrical impedance analysis remains an independent predictive marker in HIV-infected patients in the era of highly active antiretroviral treatment. , 2000, The American journal of clinical nutrition.

[5]  G. Beall,et al.  Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. , 2000, JAMA.

[6]  A. Klibanski,et al.  Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men. , 2000, The Journal of clinical endocrinology and metabolism.

[7]  T. Barbieri,et al.  Resistance Exercise and Supraphysiologic Androgen Therapy in Eugonadal Men With HIV-Related Weight Loss , 1999 .

[8]  C. Hamilton,et al.  The use of a transscrotal testosterone delivery system in the treatment of patients with weight loss related to human immunodeficiency virus infection. , 1999, The American journal of medicine.

[9]  B. Gazzard,et al.  Short-term growth hormone administration at the time of opportunistic infections in HIV-positive patients. , 1999, AIDS.

[10]  M. Van Loan,et al.  Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss: a randomized controlled trial. , 1999, JAMA.

[11]  S. Azen,et al.  Effects of pharmacological doses of nandrolone decanoate and progressive resistance training in immunodeficient patients infected with human immunodeficiency virus. , 1999, The Journal of clinical endocrinology and metabolism.

[12]  M. Van Loan,et al.  Effects of nandrolone decanoate therapy in borderline hypogonadal men with HIV-associated weight loss. , 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[13]  A. Klibanski,et al.  Quantitative assessment of cross-sectional muscle area, functional status, and muscle strength in men with the acquired immunodeficiency syndrome wasting syndrome. , 1999, The Journal of clinical endocrinology and metabolism.

[14]  A. Kilbourne,et al.  Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels. , 1998, The Journal of clinical endocrinology and metabolism.

[15]  D. Schoenfeld,et al.  Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: a pilot study. , 1998, The Journal of clinical endocrinology and metabolism.

[16]  A. Klibanski,et al.  Effects of Androgen Administration in Men with the AIDS Wasting Syndrome , 1998, Annals of Internal Medicine.

[17]  C. Gibert,et al.  Weight loss as a predictor of survival and disease progression in HIV infection. Terry Beirn Community Programs for Clinical Research on AIDS. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[18]  G. Coodley,et al.  A trial of testosterone therapy for HIV‐associated weight loss , 1997, AIDS.

[19]  A. Klibanski,et al.  Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting. , 1997, The Journal of clinical endocrinology and metabolism.

[20]  M. Schambelan,et al.  Cross-sectional and longitudinal evaluation of body composition in men with HIV infection. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[21]  R. Casaburi,et al.  Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. , 1997, The Journal of clinical endocrinology and metabolism.

[22]  S. Jebb,et al.  Longitudinal changes in body composition measured with a variety of methods in patients with AIDS. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[23]  A. LaMarca,et al.  Recombinant Human Growth Hormone in Patients with HIV-Associated Wasting , 1996, Annals of Internal Medicine.

[24]  D. Schade,et al.  Recombinant Human Growth Hormone, Insulin-like Growth Factor 1, and Combination Therapy in AIDS-Associated Wasting , 1996, Annals of Internal Medicine.

[25]  D. Simpson,et al.  Oxandrolone in AIDS‐wasting myopathy , 1996, AIDS.

[26]  A. Guccione,et al.  Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. , 1996, The Journal of clinical endocrinology and metabolism.

[27]  K. Nair,et al.  Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men--a clinical research center study. , 1996, The Journal of clinical endocrinology and metabolism.

[28]  P. D. Lee.  A randomized, placebo-controlled trial of combined insulin-like growth factor I and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection [published erratum appears in J Clin Endocrinol Metab 1996 Oct;81(10):3696] , 1996 .

[29]  J. Pivarnik,et al.  A randomized, placebo-controlled trial of combined insulin-like growth factor I and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection. , 1996, The Journal of clinical endocrinology and metabolism.

[30]  J. Pivarnik,et al.  Changes in body composition of human immunodeficiency virus-infected males receiving insulin-like growth factor I and growth hormone. , 1996, The Journal of clinical endocrinology and metabolism.

[31]  J. Gold,et al.  Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection , 1996, AIDS.

[32]  U. Hengge,et al.  Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection , 1996, British Journal of Nutrition.

[33]  S A Jebb,et al.  Energy expenditure and wasting in human immunodeficiency virus infection. , 1995, The New England journal of medicine.

[34]  U. Süttmann,et al.  Incidence and prognostic value of malnutrition and wasting in human immunodeficiency virus-infected outpatients. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[35]  J. V. Von Roenn,et al.  Megestrol Acetate in Patients with AIDS-related Cachexia , 1994, Annals of Internal Medicine.

[36]  S. Gorbach,et al.  Nutritional aspects of HIV infection. , 1994, Infectious disease clinics of North America.

[37]  A. Hoffman,et al.  Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome. , 1994, Journal of Clinical Endocrinology and Metabolism.

[38]  M. Wallace,et al.  Changes in the mix of AIDS-defining conditions. , 1993, The New England journal of medicine.

[39]  M. Schambelan,et al.  Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. , 1993, The Journal of clinical endocrinology and metabolism.

[40]  P. Guenter,et al.  Relationships among nutritional status, disease progression, and survival in HIV infection. , 1993, Journal of acquired immune deficiency syndromes.

[41]  G. Griffin,et al.  Prospective analysis of patterns of weight change in stage IV human immunodeficiency virus infection. , 1993, The American journal of clinical nutrition.

[42]  K. Feingold,et al.  Resting energy expenditure, caloric intake, and short-term weight change in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. , 1992, The American journal of clinical nutrition.

[43]  T. Ziegler,et al.  Use of human growth hormone combined with nutritional support in a critical care unit. , 1990, JPEN. Journal of parenteral and enteral nutrition.

[44]  J. Wang,et al.  Effect of home total parenteral nutrition on body composition in patients with acquired immunodeficiency syndrome. , 1990, JPEN. Journal of parenteral and enteral nutrition.

[45]  J. Wang,et al.  Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. , 1989, The American journal of clinical nutrition.

[46]  D. Wilmore,et al.  Growth Hormone Stimulates Protein Synthesis during Hypocaloric Parenteral Nutrition: Role of Hormonal‐Substrate Environment , 1988, Annals of surgery.

[47]  Michael A. Dempsey,et al.  Endocrine disorders in men infected with human immunodeficiency virus. , 1988, The American journal of medicine.

[48]  D. Halliday,et al.  Protein and energy metabolism with biosynthetic human growth hormone after gastrointestinal surgery. , 1987, Annals of surgery.

[49]  J. Wang,et al.  Body composition studies in patients with the acquired immunodeficiency syndrome. , 1985, The American journal of clinical nutrition.

[50]  A. Dalgleish,et al.  SLIM DISEASE: A NEW DISEASE IN UGANDA AND ITS ASSOCIATION WITH HTLV-III INFECTION , 1985, The Lancet.